Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
Subscribe To Our Newsletter & Stay Updated
